Exchange: NASDAQ·Updated 04:10 PM EST
WVE logo

WVE Wave Life Sciences Ltd

$2.77
$0.07
(2.46%)
Today
Closed $2.77
$0.00
(0.00%)
After Hours
Reported EarningsOct 27
Mkt Cap$560.13M
Vol2.2M

About WVE

Wave Life Sciences, Inc. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It develops and commercializes a pipeline of RNA medicines across a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Cambridge, MA.
54

Neutral Sentiment

How do you feel about WVE?

hichemben
$WVE Excellent chat today, CEO was very confident of Wave leading candidates 🚀 He removed ambiguity around patient response consistency on 006 and reframed 007 into a large-market commercial asset🙌🏼 The ER's call next week, followed by 006 readout mid Nov! Let's gooo💎
1
10
Gurujoe
$WVE| AASLD 2026 — WVE-006 Late-Breaking Presentation What’s new? Today’s AASLD presentation formally highlights RestorAATion-2’s human RNA-editing results, reinforcing the potential for a single therapy addressing BOTH lung and liver disease in AATD. Importantly, the efficacy figures largely confirm May’s disclosures rather than represent a new data breakthrough. Positives: • Functional M-AAT reached 64% of total AAT, approaching the protective MZ-like phenotype. • Mutant Z-AAT reduced up to 71%. • Endogenous AAT increased during inflammatory responses. • Editing durability of at least three months after dosing. • Favorable safety, no serious AEs. • FDA alignment on a potential accelerated approval pathway. Negatives/Risks: • Limited incremental efficacy data today. • Absolute functional M-AAT trough levels and clinical lung protection remain unproven. • No direct evidence of reduced hepatic fibrosis. • Small cohorts; 600 mg monthly multidose data pending. Bottom line: Compelling proof of mechanism with potentially best-in-class differentiation, but clinical benefit remains to be demonstrated. The upcoming 600 mg data could be the real valuation inflection point. Still bullish and holding. $WVE #RNAEditing #AASLD2026
10
Nasfact
$WVE data is good. Why no data release yet? PR coming after hours? I don't know why, but I think a buyout is possible. Many catalysts are coming, very few information is getting released, price is controlled since month... Based on pipeline and compared to marketcap this is to low of a share price IMO. Lets see how controlled this is going to stay...
10
Gurujoe
$WVE | November 9 AASLD — Potential Best-in-Class AATD Therapy, FDA Alignment & Partnership Optionality Monday’s late-breaking WVE-006 RestorAATion-2 presentation could be an important clinical and valuation catalyst for Wave Life Sciences. 1. Significant Market Opportunity Wave estimates approximately 200,000 individuals with Pi*ZZ AATD across the U.S. and Europe. The addressable market could support multibillion-dollar annual sales, depending on diagnosis, treatment eligibility, pricing and penetration. 2. Potential Best-in-Class Differentiation WVE-006 targets BOTH major manifestations of AATD: • Reduces toxic mutant Z-AAT associated with liver disease. • Restores functional wild-type M-AAT to potentially protect the lungs. • Restores the body’s dynamic AAT response. • Offers convenient subcutaneous administration. Previously reported results demonstrate dose-dependent mutant protein reduction, functional protein restoration and an MZ-like phenotype, with encouraging safety and no reported liver toxicities. 3. FDA Regulatory De-Risking Wave has secured FDA alignment on key elements of a potentially accelerated registrational pathway: • Single planned two-year registrational trial. • One-year interim analysis supporting potential accelerated approval. • FDA support for measuring M-AAT and Z-AAT biomarkers. This could substantially improve development efficiency, although approval remains contingent on successful clinical results and FDA review. 4. Strategic Partnership / Licensing Catalyst Wave regained full worldwide rights to WVE-006 from GSK in February 2026, retaining control of a potentially valuable AATD franchise. Strong clinical results could enhance licensing attractiveness, potentially supporting significant upfront payments, development milestones and royalties. The September appointment of former Sanofi Global Head of Partnering Monika Vnuk as Chief Business Officer further strengthens Wave’s business-development capabilities. Importantly, Wave can continue advancing WVE-006 independently. A partnership would represent additional financial and strategic optionality, not a prerequisite. 5. November 9 — What to Watch Additional evidence of editing efficiency, functional protein restoration, durability, dose-response and safety. The 600 mg monthly multidose cohort remains an important Q4 catalyst, although its inclusion in Monday’s presentation is not confirmed. 6. Broader Platform Valuation Clinical validation of WVE-006 could materially reduce perceived RNA-editing platform risk, strengthening the investment case for WVE-008 in PNPLA3 liver disease and future programs. With $431M in cash and securities at Q3, runway into Q3 2028, an ongoing GSK collaboration and multiple clinical catalysts, Wave has meaningful strategic flexibility. My investment thesis: WVE-006 is increasingly positioned as a potential best-in-class AATD therapy. Positive November 9 results could support a meaningful upward reassessment of risk-adjusted NPV through clinical de-risking, regulatory progress, commercial opportunity and partnership optionality. Bullish heading into Monday. Long
10
Nasfact
$WVE paying close attention here! Valuation is way to low IMO. Multiple Irons in the fire... AATD is a no brainer... BEAM is competitor but expecting faster approval for WVE. Pipeline updates will be coming. Institutions are backing this smalll cap big time. Started with a high 5 figure position. Looking forward to R&D day.
10
hichemben
$WVE I saw this update 2 days ago on their LinkedIn page🙌🏼 Bringing on Gemma Mandell as VP, Head of Regulatory directly reinforces Wave’s shift from an early discovery biotech into a commercial registrational company🔥 Let's gooo🚀🚀🚀 Why now? Gemma spent 6.5 years at Blueprint Medicines as VP of Global Regulatory Sciences: - At Blueprint, regulatory leadership navigated and executed the FDA and EMA approvals for AYVAKIT® - Her operational background is built on accelerated approval pathways and negotiate protocol with FDA
10
Axia
$WVE next few weeks should be very interesting. Q3 earnings call scheduled today for Tuesday Oct 27
9
Benitocalixto
$WVE I listened to CEO Bolno at the Chardan biotech conference, really interesting. The analyst R&D day is set for Nov 4th. The WVE-006 data for 600mg AATD will probably be released then. Now through 2027, there are multiple WVE-007 trials ongoing - various cohorts for combo GLP1 therapy, maintenance, diabetics and unhealthy high BMI patients (vs. the simple safety trial with a healthy 30 BMI cohort that crushed the stock). We still don’t have this data from WVE, rolling data will be released in 2027. Also, discussion about ALK7 and delivery to adipose fat tissue (vs hepatic) - we will know more after ARWR reports data this quarter on ALK7. Adipose delivery is new vs. trusted and tested GalNac (liver delivery only) for safety over many years. ALK7 will need at least 5 years of testing and safety before it becomes trusted. The FDA will want detailed data on where it goes and long-term toxicology in all tissue it reaches, including pancreas and other body tissues.
8
nskanthbw
$WVE RNA Editing (WVE-006 for AATD): Management reiterated expectations for upcoming clinical readouts, including data from the 600 mg monthly WVE-006 cohort anticipated in Q4 2026.
8
Patrick2343
$WVE I thought buying this at 4 was a good deal. Bios are such horrible investments ever since covid. Unless you hit big on a readout all they do is go down daily and i should have known this.
5
300bigboys
$WVE New analyst commentary: More encouraging than the stock price suggests A November 16 BioSpace article⁠ discusses the WVE-007 results and reactions from Rodman & Renshaw and William Blair. Rodman & Renshaw’s interpretation is particularly interesting. The analysts believe the ObesityWeek findings support Wave’s hypothesis that patients with higher baseline BMI and greater adiposity experience stronger responses to WVE-007. They highlighted that: * The 240-mg cohort, which had the highest baseline BMI, demonstrated the strongest body-composition improvements. * The 400-mg and 600-mg cohorts had lower baseline adiposity. * Those differences could explain why higher doses didn’t produce proportionately greater fat loss. * The Phase 2a trial specifically recruits patients with BMI 35–50, potentially addressing that limitation. There are still 1-2 clinical updates/readouts they say we will get before years end.
5
300bigboys
$WVE long and bullish. Assessment of the three leading programs 🥇 WVE-006 — Closest to a potential regulatory breakthrough. It has encouraging human biomarker results and a clearer FDA pathway. The upcoming 600 mg multidose data are particularly important. Next milestone: 600 mg monthly multidose results in Q4 2026. 🥈 WVE-007 — Potentially the largest commercial opportunity. Obesity represents an enormous market, but Wave still needs to demonstrate sufficiently compelling weight-loss and body-composition benefits in larger studies. Next milestone: 600 mg single-dose data in Q4 2026, plus continued Phase 2a results and initiation of a post-GLP-1 maintenance study. 🥉 WVE-008 — Earlier-stage but scientifically intriguing. Its genetically targeted approach could differentiate it from other MASH treatments, but human proof of concept is still missing. Next milestone: Clinical trial application expected Q4 2026, potentially enabling human studies in 2027.
7
PepCF
$WVE Today is $PEPG's day, another stock in ra capital portfolio. One day it'll be our day too.
7
300bigboys
$WVE on the possibility of maverick exiting a position. Maverick is not primarily a biotechnology specialist like RA Capital. Maverick has recently demonstrated considerable enthusiasm for semiconductor investments. Here’s their top holdings: NVIDIA $611.6M 5.5% AMD $567.2M 5.1% Astera Labs $515.5M 4.7% Intel $512.3M 4.6% Alphabet $509.5M 4.6% Amazon $481.7M 4.3% My interpretation for Wave. I would distinguish Maverick from bio investors like RA Capital. RA Capital: A life-sciences specialist whose substantial WVE ownership reflects a sector-focused investment strategy. Maverick: A diversified hedge fund whose WVE investment was one of many positions competing for capital. Consequently, I would give Maverick’s departure less weight as a negative scientific signal than I would give a similarly substantial exit by RA Capital. But I wouldn’t interpret Maverick’s decision as evidence that something is wrong with WVE-006, WVE-007 or the PRISM platform.
1
2
Benitocalixto
$WVE Also, titrating the dose for ALK7 (eg maintenance and combo therapies) will need fat biopsies in order to determine how to adjust the dose over time, and it’s complicated. INHBE is a simple blood test and it’s well-known to be safe. Wall street is so hung up on the magnitude of weight loss numbers and nothing else - there’s so much more to this story.
6
hichemben
$WVE Yesterday's AASLD presentation did not provide wve006 new 600 mg multidose results, and nothing changed, we are on track for Q4 (coming weeks) along wve007 data 600 SAD #Patience💎🚀
5
johnnygogogo
$WVE leerink sucks. Most dishonest bio firm there is. One year ago, “buy the shares at $19” / yesterday “buy rating but reducing the target from $12 to $10” F off
5
Benitocalixto
$WVE It’s clear that Bolno knows that the stock got knocked down because of the debate of ALK7 vs Activin E (INHBE gene). He did made the case for why Activin E is far superior. WVE got crushed this past spring and RA still added to an 18% position. They sit on the board. They obviously knew that ALK7 isn’t a big threat in INHBE..
5
Nasfact
$WVE 431 mio Cash... plus assets... This M/ price is a joke. Plan on adding. Sell off over done. Green active and brown color looking for partner...
3
DarbyCash
$WVE can someone help me out — I did a decent dive into the PN backbone technology. I appreciate that it helps with PK, PD, duration of RNA silencing, and the benefits of a single eutomer (over a racemix mixture of 2^N stereoisomers), but I’m still struggling to understand how that is all worthwhile when you can just increase the dosing frequency eg Arrowhead to a few times / year.
3

Advertisement|Remove ads.